Myovant and Pfizer’s path to securing a second nod for Myfembree gets hazy — and investors react quickly  

Myovant was on tap for a May 6 decision on a supplemental NDA for its three-in-one pill Myfembree, aiming to treat moderate to severe pain associated with endometriosis. With an FDA nod, Myovant would get a $100 million regulatory milestone from partner Pfizer.